Next Article in Journal
Effect of Centrifugal Shot Peening on the Surface Properties of Laser-Cut C45 Steel Parts
Previous Article in Journal
Human Mesenchymal Stem Cell Combined with a New Strontium-Enriched Bioactive Glass: An ex-vivo Model for Bone Regeneration
Previous Article in Special Issue
PGlu-Modified Nanocrystalline Cellulose Improves Mechanical Properties, Biocompatibility, and Mineralization of Polyester-Based Composites
Open AccessArticle

Hybrid Systems Based on Talc and Chitosan for Controlled Drug Release

LIMAV, Interdisciplinary Laboratory for Advanced Materials, Federal University of Píaui, Campus Universitário Ministro Petrônio Portella, Teresina, Piaui 64049-550, Brazil
Campus Senador Helvídio Nunes Barros—UFPI/CHHNB, Picos, Píaui 64607-607, Brazil
Research Center on Biotechnology—Uniara, Araraquara, São Paulo 14801-340, Brazil
Biopolymers and Biomaterials Laboratory (BIOPOLMat)—Uniara, Araraquara, São Paulo 14801-340, Brazil
Federal Institute of Piauí, Teresina-Central Campus, IFPI, Teresina 64000-040, PI, Brazil
Department of Pharmacy and Pharmaceutical Technology, University of Granada, 18071 Granada, Spain
Author to whom correspondence should be addressed.
Materials 2019, 12(21), 3634;
Received: 10 September 2019 / Revised: 19 October 2019 / Accepted: 22 October 2019 / Published: 5 November 2019
(This article belongs to the Special Issue Advances in Polysaccharide Biomaterials)
Inorganic matrices and biopolymers have been widely used in pharmaceutical fields. They show properties such as biocompatibility, incorporation capacity, and controlled drug release, which can become more attractive if they are combined to form hybrid materials. This work proposes the synthesis of new drug delivery systems (DDS) based on magnesium phyllosilicate (Talc) obtained by the sol–gel route method, the biopolymer chitosan (Ch), and the inorganic-organic hybrid formed between this matrix (Talc + Ch), obtained using glutaraldehyde as a crosslink agent, and to study their incorporation/release capacity of amiloride as a model drug. The systems were characterized by X-ray diffraction (XRD), Therma analysis TG/DTG, and Fourier-transform infrared spectroscopy (FTIR) that supported the DDS’s formation. The hybrid showed a better drug incorporation capacity compared to the precursors, with a loading of 55.74, 49.53, and 4.71 mg g−1 for Talc + Ch, Talc, and Ch, respectively. The release assays were performed on a Hanson Research SR-8 Plus dissolver using apparatus I (basket), set to guarantee the sink conditions. The in vitro release tests showed a prolongation of the release rates of this drug for at least 4 h. This result proposes that the systems implies the slow and gradual release of the active substance, favoring the maintenance of the plasma concentration within a therapeutic window. View Full-Text
Keywords: phyllosilicate; chitosan; hybrid; amiloride; drug release phyllosilicate; chitosan; hybrid; amiloride; drug release
Show Figures

Figure 1

MDPI and ACS Style

Lima, L.C.B.; Coelho, C.C.; Silva, F.C.; Meneguin, A.B.; Barud, H.S.; Bezerra, R.D.S.; Viseras, C.; Osajima, J.A.; Silva-Filho, E.C. Hybrid Systems Based on Talc and Chitosan for Controlled Drug Release. Materials 2019, 12, 3634.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop